Navigation Links
A bacterial genome reveals new targets to combat infectious disease

More than a billion people are at risk for infection with filarial nematodes, parasites that cause elephantiasis, African river blindness, and other debilitating diseases in more than 150 million people worldwide. The nematodes themselves play host to bacteria that live within their cells, but in this case, the relationship is classic mutualism, with each benefiting from the other. Indeed, the Wolbachia bacterium is so crucial to its host nematode that apparently eradicating it with antibiotics severely compromises the nematode's ability to complete its life cycle within its human host. Thus, understanding the details of this relationship may help identify new strategies for controlling diseases caused by filarial nematodes. In a new study published in the freely-available online journal PLoS Biology, Barton Slatko and colleagues present the complete DNA sequence of the Wolbachia pipientis strain within Brugia malayi, a parasitic nematode responsible for lymphatic filariasis.

This Wolbachia genome is small, only about a million base pairs, and many metabolically critical genes have degraded through mutation to the point of uselessness. This phenomenon, called reductive evolution, is typical of long-term symbioses, as the two partners increasingly complement one another's biochemical activities.

Slatko and colleagues enumerate a variety of pathways that have either been degraded or preserved, and highlight patterns in the genome structure through comparisons with other bacteria. For example, Wolbachia can manufacture some essential metabolic coenzymes, which do not appear to be made by its host. Conversely, it cannot synthesize amino acids and a variety of other vitamins and cofactors, and probably depends on the nematode to supply them.

One discovery of possible significance is the presence in the bacterium of the synthetic pathway for heme - the oxygen-carrying iron component of hemoglobin. The nematode may require heme for synthesis of devel opmental hormones, so Wolbachia's heme pathway may be an inviting target for therapy against nematode infection. Since no new antifilarial has been developed in two decades, these results may quickly lead to new therapeutic strategies against these parasites.

###

Citation: Foster J, Ganatra M, Kamal I, Ware J, Makarova K, et al. (2005) The Wolbachia genome of Brugia malayi: Endosymbiont evolution within a human pathogenic nematode. PLoS Biol 3(4): e121.


'"/>

Source:PLoS Biology


Related biology news :

1. Anti-bacterial additive widespread in U.S. waterways
2. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
3. Scientists discover that host cell lipids facilitate bacterial movement
4. Protein prevents detrimental immune effects of bacterial sepsis
5. Researchers develop new method for facile identification of proteins in bacterial cells
6. A virus-like hitchhiker may trigger bacterial meningitis
7. Using the genomic shortcut to predict bacterial behavior
8. Eliminating bacterial infections out of thin air
9. Student scientists create living bacterial photographs
10. Researchers identify molecular anchor that allows bacterial invasion of central nervous system
11. Scientists determine structure of enzyme that disrupts bacterial virulence
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
Breaking Biology Technology: